OncoMatch/Clinical Trials/NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT06235229 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies GC012F for multiple myeloma.
Treatment: GC012F — This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: proteasome inhibitor
Prior therapy should include proteasome inhibitors (PIs)
Must have received: immunomodulatory drug
Prior therapy should include immunomodulatory drugs (IMiDs)
Must have received: anti-CD38 antibody
Prior therapy should include anti-CD38 antibodies
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T products for any target
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: Patients undergoing allo-HSCT who have discontinued all immunosuppressive drugs for 6 weeks prior to leukapheresis and have no manifestations of graft-versus-host disease (GVHD) may be enrolled.
Received an allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 6 months prior to leukapheresis
Cannot have received: autologous hematopoietic stem cell transplantation
Received an autologous hematopoietic stem cell transplantation (auto-HSCT) within ≤ 12 weeks prior to leukapheresis
Lab requirements
Blood counts
Neutrophil count ≥ 0.75×10^9/L (growth factor support allowed, but not within 7 days prior to screening); Hemoglobin ≥ 8.0 g/dL (no red blood cell transfusion within 7 days prior to screening, recombinant human erythropoietin allowed); Platelet count ≥ 50×10^9/L (no platelet transfusion within 7 days prior to screening); Lymphocyte count ≥ 0.3×10^9/L
Kidney function
Creatinine clearance ≥ 40 mL/min, calculated by Cockcroft-Gault
Liver function
ALT/AST ≤ 3× ULN; Total bilirubin ≤ 2× ULN (Gilbert syndrome: direct bilirubin ≤ 1.5× ULN)
Cardiac function
LVEF ≥ 45% with no evidence of pericardial effusion as diagnosed by echocardiography; No clinically significant electrocardiogram abnormality observed
Adequate functional reserve of organs: ... see details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06235229 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages